Thompson Investment Management Inc. Purchases 12,651 Shares of Pfizer Inc. (NYSE:PFE)

Thompson Investment Management Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 3.6% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 368,225 shares of the biopharmaceutical company’s stock after buying an additional 12,651 shares during the period. Pfizer comprises approximately 1.5% of Thompson Investment Management Inc.’s holdings, making the stock its 14th largest position. Thompson Investment Management Inc.’s holdings in Pfizer were worth $10,218,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Advisor OS LLC increased its position in shares of Pfizer by 1.0% during the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after acquiring an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC increased its position in shares of Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after acquiring an additional 371 shares during the last quarter. Lantz Financial LLC increased its position in shares of Pfizer by 1.3% during the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after acquiring an additional 381 shares during the last quarter. King Wealth Management Group increased its position in shares of Pfizer by 2.4% during the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 388 shares during the last quarter. Finally, Advance Capital Management Inc. increased its position in shares of Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after acquiring an additional 391 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 2.0 %

PFE stock traded down $0.57 during midday trading on Wednesday, reaching $27.42. 14,858,384 shares of the company were exchanged, compared to its average volume of 40,944,512. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The stock’s 50-day simple moving average is $27.77 and its 200 day simple moving average is $27.69. The company has a market cap of $155.38 billion, a price-to-earnings ratio of -463.42, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter last year, the company earned $1.23 earnings per share. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a $0.42 dividend. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.13%. Pfizer’s payout ratio is -2,799.53%.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.